Clareo Health | Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
PharmaMar
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Voluntarily signed and dated written informed consent (IC)
Age between 18 and 75 years
Women of childbearing potential must have pregnancy excluded by appropriate testing before study entry.
Life expectancy ≥ 3 months.
Patients with a histologically/cytologically confirmed diagnosis of unresectable Metastatic Breast Cancer, Pancreatic Cancer or metastatic Colorectal Cancer.
You may not be if
Three or more prior chemotherapy-containing lines for advanced disease.
Prior treatment with PM01183 or with capecitabine containing therapy for advanced disease.
History within the last year or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically relevant valvular heart disease or symptomatic arrhythmia or any asymptomatic ventricular arrhythmia requiring ongoing treatment.
Ongoing chronic hepatopathy of any origin.
Active uncontrolled infection.
Patients with dyspnea who are requiring any ongoing oxygen support.
Known human immunodeficiency virus (HIV) infection.
Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study.
Men or women of childbearing potential who are not using an effective method of contraception
